

---

# RUTH DUNCAN

---

KEYNOTE SPEAKER AT:

## NANOTECHNOLOGIES IN HEALTH. CURRENT CHALLENGES AND FUTURE PROSPECTS



October, 9<sup>th</sup>, 10<sup>th</sup> and 11<sup>th</sup>, 2013, Barcelona

---

**Ruth Duncan**, Director of the Centre for Polymer Therapeutics at the [Welsh School of Pharmacy](#), Cardiff University, UK

Ruth Duncan also currently holds the honorary positions of Professor Emerita in Cardiff University, and Visiting Professor at the University of Greenwich and Centro de Investigación Príncipe Felipe, Valencia. She is also a member of a number of Institutional and International Advisory Boards and Committees; e.g. President of the Advisory Board of the Spanish Ciber-bbn, and member of the Scientific Advisory Boards of the Filarete Foundation (Milan), Vall D'Hebron Research Institute (Barcelona) and the iMed Institute, Faculty of Pharmacy, University of Lisbon. After finishing her Ph.D. studies at Keele University on the mechanisms of endocytosis (1979), she established an interdisciplinary group at Keele interested in the rational design of polymeric anticancer conjugates (Cancer Research Campaign's Polymer Controlled Drug Delivery Group). After licensing to Farmitalia Carlo Erba the first polymer anticancer conjugates developed together with the Institute of Macromolecular Chemistry Prague she joined the company in 1992 in Milan as Head of New Technologies/Project Team Leader where she was responsible of transferring the first synthetic polymer anticancer conjugates arising from her work into clinical trials. Returning to academia in 1994 she established the Centre for Polymer Therapeutics at the London School of Pharmacy and in 2000 the group transferred to Cardiff She was elected Co-Chair of the Gordon Research Conference on Drug Carriers in Biology and Medicine in 1998, and in 2004 was elected the Science Chair of the British Pharmaceutical Conference. She is a past member of the CPS sub committee of the UK Medicines and Health Regulatory Agency and is currently a member of the European Medicines Agency AD Hoc Advisory Committee on Nanomedicine.

B-DEBATE IS AN INITIATIVE OF:

WITH THE COLLABORATION OF:



[www.bdebate.org](http://www.bdebate.org)